View Item 

Show simple item record

Sotrastaurin, a Novel Small Molecule Inhibiting Protein‐Kinase C: Randomized Phase II Study in Renal Transplant Recipients
dc.contributor.authorFriman, S.en_US
dc.contributor.authorArns, W.en_US
dc.contributor.authorNashan, B.en_US
dc.contributor.authorVincenti, F.en_US
dc.contributor.authorBanas, B.en_US
dc.contributor.authorBudde, K.en_US
dc.contributor.authorCibrik, Diane M.en_US
dc.contributor.authorChan, L.en_US
dc.contributor.authorKlempnauer, Juergenen_US
dc.contributor.authorMulgaonkar, Shamkant P.en_US
dc.contributor.authorNicholson, M.en_US
dc.contributor.authorWahlberg, J.en_US
dc.contributor.authorWissing, K.‐m.en_US
dc.contributor.authorAbrams, K.en_US
dc.contributor.authorWitte, S.en_US
dc.contributor.authorWoodle, E. S.en_US
dc.date.accessioned2011-11-10T15:31:09Z
dc.date.available2012-09-04T15:27:12Zen_US
dc.date.issued2011-07en_US
dc.identifier.citationFriman, S.; Arns, W.; Nashan, B.; Vincenti, F.; Banas, B.; Budde, K.; Cibrik, D.; Chan, L.; Klempnauer, J.; Mulgaonkar, S.; Nicholson, M.; Wahlberg, J.; Wissing, K.‐m. ; Abrams, K.; Witte, S.; Woodle, E. S. (2011). "Sotrastaurin, a Novel Small Molecule Inhibiting Proteinâ Kinase C: Randomized Phase II Study in Renal Transplant Recipients." American Journal of Transplantation 11(7). <http://hdl.handle.net/2027.42/86809>en_US
dc.identifier.issn1600-6135en_US
dc.identifier.issn1600-6143en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/86809
dc.publisherBlackwell Publishing Incen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherAllotransplantationen_US
dc.subject.otherCalcineurin Inhibitor Toxicityen_US
dc.subject.otherDrug Developmenten_US
dc.subject.otherEfficacyen_US
dc.subject.otherImmunosuppressionen_US
dc.subject.otherMycophenolic Aciden_US
dc.subject.otherRenal Functionen_US
dc.subject.otherSafetyen_US
dc.subject.otherTacrolimusen_US
dc.subject.otherT‐Cell Activationen_US
dc.titleSotrastaurin, a Novel Small Molecule Inhibiting Protein‐Kinase C: Randomized Phase II Study in Renal Transplant Recipientsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherTransplant Institute, Sahlgrenska University Hospital, Göteborg, Swedenen_US
dc.contributor.affiliationotherMerheim Medical Center, Cologne General Hospital, Cologne, Germanyen_US
dc.contributor.affiliationotherUniversity Medical Center Hamburg‐Eppendorf, Hamburg, Germanyen_US
dc.contributor.affiliationotherUCSF Kidney Transplant Service, San Francisco, CAen_US
dc.contributor.affiliationotherDepartment of Internal Medicine II, University Medical Center Regensburg, Regensburg, Germanyen_US
dc.contributor.affiliationotherDepartment of Nephrology, Charité University, Berlin, Germanyen_US
dc.contributor.affiliationotherDepartment of Transplant/Nephrology, University of Colorado, Aurora, COen_US
dc.contributor.affiliationotherViszeral‐ und Transplantationschirugie, Medizinische Hochschule Hannover, Hannover, Germanyen_US
dc.contributor.affiliationotherSt Barnabas Medical Center, Livingston, NJen_US
dc.contributor.affiliationotherUniversity of Leicester, Leicesteren_US
dc.contributor.affiliationotherDepartment of Surgery, University of Uppsala, Uppsala, Swedenen_US
dc.contributor.affiliationotherDepartment of Nephrology, ULB Hopital Erasme, Brussels, Belgiumen_US
dc.contributor.affiliationotherNovartis Pharmaceuticals Corporation, East Hanover, NJen_US
dc.contributor.affiliationotherNovartis Pharma AG, Basel, Switzerlanden_US
dc.contributor.affiliationotherSurgery/Transplant Division, University of Cincinnati, Cincinnati, OHen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/86809/1/j.1600-6143.2011.03538.x.pdf
dc.identifier.doi10.1111/j.1600-6143.2011.03538.xen_US
dc.identifier.sourceAmerican Journal of Transplantationen_US
dc.identifier.citedreferenceMeier‐Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378 – 383.en_US
dc.identifier.citedreferenceHalloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715 – 2729.en_US
dc.identifier.citedreferenceVincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282 – 1287.en_US
dc.identifier.citedreferenceEkberg H, Grinyo J, Nashan B et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR study. Am J Transplant 2007; 7: 560 – 570.en_US
dc.identifier.citedreferenceUS Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 1999; 34: 296 – 303.en_US
dc.identifier.citedreferencePrince O, Savic S, Dickenmann M, Steiger J, Bubendorf L, Mihatsch MJ. Risk factors for polyoma virus nephropathy. Nephrol Dial Transplant 2009; 24: 1024 – 1033.en_US
dc.identifier.citedreferencePietruck F, Klempnauer J, Arns W et al. Efficacy and Safety of Everolimus (RAD) / Enteric‐coated Mycophenolate Sodium (EC‐MPS) after Calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: Final results of the ZEUS trial. Am J Transplant 2009; s2: 499.en_US
dc.identifier.citedreferenceWeir M, Mulgaonkar S, Pearson T et al. Mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2‐year outcomes of the spare‐the‐nephron (STN) trial. Am J Transplant 2009; s2: 200.en_US
dc.identifier.citedreferenceEkberg H, Tedesco‐Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562 – 2575.en_US
dc.identifier.citedreferenceBuchler M, Caillard S, Barbier S et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6‐month course of steroids. Am J Transplant 2007; 7: 2522 – 2531.en_US
dc.identifier.citedreferenceSpitaler M, Cantrell DA. Protein kinase C and beyond. Nat Immunol 2004; 5: 785 – 790.en_US
dc.identifier.citedreferenceGuo B, Su TT, Rawlings DJ. Protein kinase C family functions in B‐cell activation. Curr Opin Immunol 2004; 16: 367 – 373.en_US
dc.identifier.citedreferenceMecklenbrauker I, Saijo K, Zheng NY, Leitges M, Tarakhovsky A. Protein kinase Cdelta controls self‐antigen‐induced B‐cell tolerance. Nature 2002; 416: 860 – 865.en_US
dc.identifier.citedreferenceBauer B, Krumbock N, Ghaffari‐Tabrizi N et al. T cell expressed PKCtheta demonstrates cell‐type selective function. Eur J Immunol 2000; 30: 3645 – 3654.en_US
dc.identifier.citedreferencePfeifhofer C, Gruber T, Letschka T et al. Defective IgG2a/2b class switching in PKC alpha−/− mice. J Immunol 2006; 176: 6004 – 6011.en_US
dc.identifier.citedreferenceWagner J, Evenou J‐P, Zenke G et al. The first‐in‐class oral protein kinase C (PKC) inhibitor NVP‐AEB071 (AEB) prolongs renal allograft survival in non‐human primates (NHP) and suppresses lymphocyte proliferation at safe exposures in human proof‐of‐concept studies. Transplantation 2006; 82 (Abstract 57): 86.en_US
dc.identifier.citedreferenceBruns C, Pally C, Beerli C et al. NVP‐AEB071 (AEB), a novel oral inhibitor of early T‐cell activation, prolongs rat cardiac allograft survival when used alone and in combination with cyclosporine, everolimus or FTY720. Transplantation 2006; 1 (Abstract 741): 316.en_US
dc.identifier.citedreferenceBigaud M, Wieczorek G, Riesen S et al. NVP‐AEB071 (AEB), a novel oral inhibitor of early T‐cell activation, prolongs the survival of non‐human primate (NHP) kidney allografts when used as monotherapy or at non‐effective doses combined with a non‐effective dose of cyclosporine (CsA). Transplantation 2006; 1 (Abstract 546): 250.en_US
dc.identifier.citedreferenceBigaud M, Wieczorek G, Preussing E et al. NVP‐AEB071 (AEB), the novel oral inhibitor of protein kinase C (PKC) and early T‐cell activation, prolongs non‐human primates (NHP) kidney allograft survival when combined with everolimus (RAD), ERL080 (ERL) or FTY720 (FTY) without calcineurin inhibitor (CNI). Transplantation 2006; 1 (Abstract 550): 251 – 252.en_US
dc.identifier.citedreferenceSkvara H, Dawid M, Kleyn E et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest 2008; 118: 3151 – 3159.en_US
dc.identifier.citedreferenceBudde K, Sommerer C, Becker T et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: First clinical results in renal‐transplant recipients. Am J Transplant 2010; 10: 571 – 581.en_US
dc.identifier.citedreferenceFlytstrom I, Stenberg B, Svensson A, Bergbrant IM. Methotrexate vs. ciclosporin in psoriasis: Effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158: 116 – 121.en_US
dc.identifier.citedreferenceRacusen LC, Colvin RB, Solez K et al. Antibody‐mediated rejection criteria—an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708 – 714.en_US
dc.identifier.citedreferenceCoresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1 – 12.en_US
dc.identifier.citedreferenceSlade A, Pfrunder A, Koelle EU, Seiberling M, Schmouder R. NVP‐AEB071 pharmacokinetics: Combination with mycophenolate mofetil (Cellcept) is safe and does not result in an interaction. Transplantation 2006; 1 (Abstract 2436): 866.en_US
dc.identifier.citedreferenceSrinivas TR, Meier‐Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: Objectives and interim result. Clin J Am Soc Nephrol 2008; 2: S101 – S116.en_US
dc.identifier.citedreferenceVincenti F, Charpentier B, Vanrenterghem Y et al. A phase III study of belatacept‐based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010: 535 – 546.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1600-6143.2011.03538.x.pdf
Size:
321.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.